SLC5A2 and chronic kidney disease: In the CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials, treatment with SGLT2inhibitors also reduced incident ESKD and slowed eGFR decline significantly overthe chronic phases of treatment.6,7,47 Despite the dip in eGFRassociated with SGLT2 inhibitor initiation, the mean eGFR in patients takingSGLT2 inhibitors was higher than that in patients taking placebo at the end ofeach of the studies.